{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Objective": {
        "score": 1,
        "evidence": "Purpose: To evaluate the changes in functional status and quality of life after TAVR."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Two reviewers independently extracted the mean change (follow-up \u2013 baseline) in primary outcomes."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Most studies showed a clinically important decrease in NYHA class at 6\u201311 months (range: \u22120.8, \u22122.1), 12\u201323 months (\u22120.8, \u22122.1), 24\u201335 months (\u22121.2, \u22122.6), and \u226536 months (\u22121.2, \u22121.6)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 4,
    "max_score": 25
  },
  "model": "gpt-4o"
}